Tisagenlecleucel
Kymriah (tisagenlecleucel) is a cell pharmaceutical. Tisagenlecleucel was first approved as Kymriah on 2018-08-22. It has been approved in Europe to treat large b-cell lymphoma diffuse and precursor b-cell lymphoblastic leukemia-lymphoma.
Trade Name | Kymriah |
---|---|
Common Name | Tisagenlecleucel |
Indication | large b-cell lymphoma diffuse, precursor b-cell lymphoblastic leukemia-lymphoma |
Drug Class |
